Day: November 13, 2019

DEER PARK, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has entered into a $10 million debt facility with SWK Holdings Corporation.“We are pleased to secure this essentially non-dilutive financing, which will allow us to continue pursuing value-enhancing business development transactions while we invest in the commercial launch of Biorphen and the planned launch of ET-105 in early 2020,” said Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals. “We are excited to be partnering with SWK, and we appreciate their confidence in Eton’s long-term potential.”About SWK HoldingsSWK Holdings Corporation is a publicly traded, specialized finance company with a focus on the...

Iceland Seafood International (“Iceland Seafood”) is delighted to announce it has signed a share purchase agreement in relation to its purchase of Elba Seafood ehf, the holding company of Elba S.L. in SpainIceland Seafood announced on November 7th it had agreed on heads of terms to acquire Elba S.L. in Spain.  Today on November 13th a share purchase agreeement has been signed with GPG Seafood ehf and IceMar ehf on the acquisition.  Iceland Seafood is acquiring Elba Seafood ehf, a single pupose vehicle that owns 100% of Elba S.L. All terms of the acquisition remains as previously announced and the acquisition is subject to customary conditions such as satisfactory Due Diligence review and board approval. Further informationIceland Seafood International hfBjarni Ármannsson, bjarni.armannsson@icelandseafood.com 

TORONTO, Nov. 13, 2019 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”) (TSX: MOZ) today announces its financial results for the third quarter ending September 30, 2019 and provides an update on the Company’s activities.Matt Manson, President and CEO stated: “Marathon made significant progress during the quarter in advancing the Valentine Gold Project in central Newfoundland. We completed a successful infill drill program in support of an updated Mineral Resource estimate, expected prior to year end. We initiated our Pre-Feasibility Study with Ausenco as lead consultant and progressed our environmental assessment work under guidelines now issued by the federal and provincial regulators. Finally, we finished the quarter with $34 million in cash following a successful equity financing in September. We anticipate...

NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) — Valley National Bancorp (NASDAQ: VLY) (“Valley”), the holding company for Valley National Bank, announced today its regular quarterly preferred and common dividends. The declared quarterly dividends to shareholders of record on December 13, 2019 are as follows:A cash dividend of $0.390625 per share to be paid December 30, 2019 on Valley’s 6.25% Fixed-To-Floating Rate Non-Cumulative Perpetual Preferred Stock Series A;A cash dividend of $0.34375 per share to be paid December 30, 2019 on Valley’s 5.50% Fixed-To-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B; andA cash dividend of $0.11 per share will be paid January 2, 2020 on Valley’s common stock.The common stock cash dividend amount per share was unchanged as compared to the previous quarterly dividend. The common cash...

LAS VEGAS, Nov. 13, 2019 (GLOBE NEWSWIRE) — Vitalibis, Inc. (OTCQB: VCBD), a technology based formulator of premium hemp-based cannabidiol (CBD) wellness products reports that it has been made aware of recent trading and promotional activity concerning VCBD common stock.  The Company has been informed that the higher than average trading volume in the Company’s stock may be the result of unauthorized promotional activity. The Company has been informed that emails promoting VCBD were sent out from unreliable sources.  The Company had no knowledge of the subject promotional campaign until notified by OTC and shares OTC’s opinion that such activities are of concern and need to be addressed immediately, and in that regard, the Company is working diligently to do so. After receiving the OTC notice, the Company conducted an inquiry...

Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to DateAcquired BioPharma Business in Partnership with AmpersandDiagnostic Test Volume Grew 16% for the Quarter and 22% Year to DateConference Call and Webcast Wednesday November 13, 2019 at 4:30 pm ETPARSIPPANY, NJ, Nov. 13, 2019 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (formerly Interpace Diagnostics Group, Inc.) (Nasdaq: IDXG), a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications, announced today that it has changed its name to Interpace Biosciences, Inc. to better reflect its new business model that combines its traditional esoteric molecular diagnostic business with its recent acquisition of the BioPharma business...

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) — Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial Officer effective November 13, 2019, but will continue to support the company by providing transition services until February 1, 2020. The company is conducting a search for a successor.“We appreciate Susan’s contributions to Pfenex and her work with the finance team during the past years in which we transformed Pfenex, ultimately leading to our FDA approval for PF708, a potential therapeutic equivalent to Forteo®,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. “Susan’s efforts have been key to our success, and we wish her all the best going forward.”Ms. Knudson said, “My time at Pfenex has been rewarding. I have...

WESTPORT, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) — Compass Diversified Holdings (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today it has priced a $100 million public offering of 4,000,000 of its 7.875% Series C Cumulative Preferred Shares with a liquidation preference of $25.00 per share. The Company has granted the underwriters a 30-day over-allotment option to purchase up to an additional 600,000 Series C Cumulative Preferred Shares. CODI intends to use the net proceeds from the offering to repay a portion of the outstanding balance of its term loan under its credit facility and for general corporate purposes. The closing is expected to occur on or about November 20, 2019, subject to customary closing conditions.Morgan Stanley, RBC Capital Markets and UBS Investment Bank are acting...

67.8% growth in  HIFU revenue through the nine month period ended September 30 over the comparable period in 201848.2% Gross margin for the nine month period ended September 30 compared to 42.3% for the comparable period in 2018Fourth consecutive quarter of profitabilityContinued to drive US sales strategy towards reference centers with sale of Focal One to Mayo Clinic Company to host a conference call on November 14, 2019 at 8:30am ESTLYON, France, November 13, 2019 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in therapeutic ultrasound, announced today financial results for the third quarter and nine months of 2019 and provided an update on strategic and operational developments. Marc Oczachowski, EDAP’s Chief Executive Officer, said, “During the third quarter, we were able to sustain the sales momentum...

On Wednesday November 13, 2019 Equinor ASA (OSE:EQNR, NYSE:EQNR), guaranteed by Equinor Energy AS, executed the following debt capital market transaction:– Issue of USD 1,000,000,000 3.25% Notes due November 18, 2049The net proceeds from the issue of the Notes will be used for general corporate purposes, which may include the repayment or purchase of existing debt or other purposes described in the prospectus supplement for the issue of Notes. The transaction will increase the financial flexibility of the company.The Notes have been fully subscribed. The settlement date is November 18, 2019.Any public offering in the United States is being made solely by means of a prospectus supplement to the prospectus included in the Registration Statement filed by Equinor ASA and Equinor Energy AS, and previously declared effective.Further information...